 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--ImmunoPrecise Antibodies Ltd. the Company or IPA NASDAQ: IPA TSX venture: IPA announces the completion of an efficacy-driven, preclinical study demonstrating further evidence of the in vivo efficacy of a four monoclonal antibody cocktail against non-overlapping epitopes, utilizing an optimized formulation and, for the first time, demonstrating therapeutic synergy of the cocktail components in vivo. Highlights of the study include: Completed 